Page last updated: 2024-10-30

metformin and Labhart-Willi Syndrome

metformin has been researched along with Labhart-Willi Syndrome in 4 studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Research Excerpts

ExcerptRelevanceReference
" Metformin is a drug used in individuals with type 2 diabetes, obesity or impaired glucose tolerance and it has a strong safety profile in children and adults."7.88Metformin as targeted treatment in fragile X syndrome. ( Dy, ABC; Eldeeb, M; Hagerman, R; Salcedo-Arellano, MJ; Tartaglia, N; Tassone, F, 2018)
" We conducted a pilot, open-label study of response to metformin in 21 children with PWS and six with early morbid obesity (EMO)."7.80Effects of metformin in children and adolescents with Prader-Willi syndrome and early-onset morbid obesity: a pilot study. ( Dykens, EM; Linville, TD; Miller, JL, 2014)
" Metformin is a drug used in individuals with type 2 diabetes, obesity or impaired glucose tolerance and it has a strong safety profile in children and adults."3.88Metformin as targeted treatment in fragile X syndrome. ( Dy, ABC; Eldeeb, M; Hagerman, R; Salcedo-Arellano, MJ; Tartaglia, N; Tassone, F, 2018)
" We conducted a pilot, open-label study of response to metformin in 21 children with PWS and six with early morbid obesity (EMO)."3.80Effects of metformin in children and adolescents with Prader-Willi syndrome and early-onset morbid obesity: a pilot study. ( Dykens, EM; Linville, TD; Miller, JL, 2014)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (25.00)18.2507
2000's0 (0.00)29.6817
2010's3 (75.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dy, ABC1
Tassone, F1
Eldeeb, M1
Salcedo-Arellano, MJ1
Tartaglia, N1
Hagerman, R1
Miller, JL1
Linville, TD1
Dykens, EM1
Cyganek, K1
Koblik, T1
Kozek, E1
Wojcik, M1
Starzyk, J1
Malecki, MT1
Chan, NN1
Feher, MD1
Bridges, NA1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Double-Blind, Placebo-Controlled Trial of Metformin in Individuals With Fragile X Syndrome (FXS)[NCT03862950]Phase 2120 participants (Anticipated)Interventional2019-05-24Recruiting
[NCT01542242]Phase 41 participants (Actual)Interventional2012-02-29Terminated (stopped due to Subject withdrew)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

4 other studies available for metformin and Labhart-Willi Syndrome

ArticleYear
Metformin as targeted treatment in fragile X syndrome.
    Clinical genetics, 2018, Volume: 93, Issue:2

    Topics: Adult; Animals; Child; Child, Preschool; Diabetes Mellitus, Type 2; Female; Fragile X Syndrome; Gluc

2018
Effects of metformin in children and adolescents with Prader-Willi syndrome and early-onset morbid obesity: a pilot study.
    Journal of pediatric endocrinology & metabolism : JPEM, 2014, Volume: 27, Issue:1-2

    Topics: Adolescent; Age of Onset; Child; Female; Glucose Tolerance Test; Humans; Hyperphagia; Male; Metformi

2014
Liraglutide therapy in Prader-Willi syndrome.
    Diabetic medicine : a journal of the British Diabetic Association, 2011, Volume: 28, Issue:6

    Topics: Adolescent; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; H

2011
Metformin therapy for diabetes in Prader-Willi syndrome.
    Journal of the Royal Society of Medicine, 1998, Volume: 91, Issue:11

    Topics: Adolescent; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Metformin; Obesity; Prader

1998